Abstract:Objective: To analyze the effect of Auer bodies on the prognosis of newly diagnosed non-M3 acute myeloid leukemia (AML) patients.Methods: From January 2017 to January 2022, 124 newly diagnosed non-M3 AML patients in Chizhou People's Hospital were retrospectively selected as the research subjects, and the patients were divided into Auer body positive group and Auer body negative group according to the presence or absence of Auer bodies in bone marrow blast cells. In the negative group, the clinical characteristics such as age, gender, disease risk classification, laboratory indicators, and success rate of induction of remission were recorded. The clinical outcome and prognosis of the patients were followed up, and the Kaplan-Meier survival curve was plotted to compare the overall survival (OS) of the two groups of patients. Results: Among the 124 non-M3 AML patients, 54 were Auer body positive and 70 were Auer body negative. There was no difference between the two groups in age, sex, medical history, fever, bleeding, pain, anemia, and disease risk classification. There was statistical significance (P>0.05), and there was a statistically significant difference in the proportion of combined cardiovascular disease and digestive system disease (P<0.05); there was no significant difference in laboratory indicators WBC, PLT, Hb, and LDH between the two groups (P>0.05). There was no significant difference in the proportion of fusion genes (P>0.05). There was no significant difference in the complete remission rate and recurrence rate between the two groups, P>0.05, but the mortality rate of the Auer body positive group was lower than that of the Auer body negative group, and the difference was statistically significant (P<0.05); Kaplan-Meier survival curves showed no statistically significant difference in progression-free survival (DFS) between the two groups (P>0.05), but the OS of the Auer body positive group was higher than that of the Auer body negative group, and the difference was statistically significant (P<0.05). Conclusion: Auer bodies are closely related to the prognosis of newly diagnosed non-M3 AML patients. Patients with positive Auer bodies are less likely to have cardiovascular disease, are more likely to have digestive system symptoms, and have a lower mortality rate. The overall survival and prognosis are better than those with negative Auer bodies. Attention should be paid.